Text Size

Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2003 by National Institute on Drug Abuse (NIDA).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00033072
First received: April 5, 2002
Last updated: October 23, 2007
Last verified: November 2003
History of Changes
  Purpose

The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral selegiline.


Condition Intervention Phase
Amphetamine-Related Disorders
 Drug: Selegiline
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Single Blind
Primary Purpose: Treatment
Official Title: Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • safety of selegiline
  • pharmacokinetic assessment

Estimated Enrollment: 16
Study Start Date: September 2001
Estimated Study Completion Date: October 2002
Detailed Description:

To determine the safety of the selegiline concurrent with d-methamphetamine challenges of 15mg & 30mg i.v. with the focus being on cardiovascular responses (HR,BP) to the i.v. methamphetamine challenges. This is a randomized, single-blind, placebo-controlled, two-arm study design to evaluate the safety of selegiline treatment, compared to placebo treatment, concurrent with i.v. methamphetamine challenges.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Volunteers who meet DSM-4 criteria for methamphetamine abuse or dependence; non-treatment seeking individuals
  • Be able to verbalize understanding of consent form; provide written informed consent

Exclusion Criteria:

  • Please contact site for more information
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00033072

Locations
United States, California
UCLA Integrated Substance Abuse Program
Los Angeles, California, United States, 90024
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Thomas Newton, M.D. University of California, Los Angeles
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00033072     History of Changes
Obsolete Identifiers: NCT00024882
Other Study ID Numbers: NIDA-CTO-0004-1
Study First Received: April 5, 2002
Last Updated: October 23, 2007
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Amphetamine-Related Disorders
Substance-Related Disorders
Mental Disorders
Methamphetamine
Amphetamine
Selegiline
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
 Central Nervous System Stimulants
Central Nervous System Agents
Therapeutic Uses
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Dopamine Uptake Inhibitors
Monoamine Oxidase Inhibitors
Enzyme Inhibitors
Neuroprotective Agents
Protective Agents
Antiparkinson Agents
Anti-Dyskinesia Agents

ClinicalTrials.gov processed this record on May 16, 2013